Navigation Links
Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
Date:3/10/2008

SOUTH SAN FRANCISCO, Calif., March 10 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule therapeutics, today announced positive interim data from the company's ongoing Phase 2 clinical trial of its lead product candidate, SNS-595, in platinum-resistant ovarian cancer patients.

In this Phase 2 clinical trial, single agent SNS-595 has demonstrated disease control (defined as stable disease, partial response or complete response) in 31 of 35 patients evaluable for best response using GOG-RECIST criteria. Of these 31 patients, one patient had a complete response, four patients had partial responses (two unconfirmed) and 26 patients had a best response of stable disease. All patients enrolled in the trial have previously failed treatment with platinum-containing regimens, and fourteen of the 35 patients have also failed prior treatment with doxorubicin HCl liposome injection (Doxil(R)). Both platinum-resistant and Doxil-resistant patients in the Phase 2 clinical trial have responded to SNS-595 therapy.

"Recurrence rates among ovarian cancer patients remain high, and the majority of refractory patients are resistant to platinum-based therapies. Based on these interim data, SNS-595 appears to be a promising, active agent in a difficult-to-treat ovarian cancer patient population," said William P. McGuire, M.D., Medical Director of the Harry and Jeanette Weinberg Cancer Institute at Franklin Square, and a lead investigator for the Phase 2 trial.

Among forty-five patients with sufficient follow-up to yield safety data, SNS-595 was generally well tolerated at a dose level of 48mg/m2
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
4. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
5. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
6. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
7. Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema
8. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
9. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
10. Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
11. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)...  Today, UL LLC, a global safety science ... electronic quality management systems (EQMS) and quality consulting ... the strengths of both organizations to support the ... comprehensive advice and guidance for successful global regulatory ... UL,s strength in regulatory services and testing offers ...
(Date:5/29/2015)... Research and Markets ( http://www.researchandmarkets.com/research/64lx2w/north_america_mri ) has ... Market - Growth, Trends And Forecasts (2014 - 2019)" ... American MRI systems market is estimated to increase from ... by 2020 with a CAGR of 2.9% between 2014 ... the open system, closed system and the standing or ...
(Date:5/29/2015)... N.J. , May 29, 2015 Actinobac ... companies originally funded with investments from Foundation Venture Capital ... at Bio International 2015 as part of the Start-Up ... announced FVCG President James M. Golubieski . ... the biotechnology industry, will be held in ...
Breaking Medicine Technology:UL and MasterControl collaborate to provide medical manufacturers full service QMS and Regulatory Submissions support 2UL and MasterControl collaborate to provide medical manufacturers full service QMS and Regulatory Submissions support 3North America MRI Market - Growth, Trends And Forecasts 2014-2019 with GE, Hitachi Medical, Philips Healthcare, Siemens Healthcare & Toshiba Medical Systems Dominating 2Foundation Venture Capital Group Portfolio Companies to be Highlighted at Bio International in June 2Foundation Venture Capital Group Portfolio Companies to be Highlighted at Bio International in June 3
... Telik, Inc.,(Nasdaq: TELK ) reported positive preclinical ... molecule inhibitors of validated cancer targets,including aurora kinases ... the,AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics ... play a key role in mitosis, or cell,division. ...
... combination IV belinostat in ovarian ... cancer reported -, - Oral belinostat demonstrated to be safe and well-tolerated in Phase ... CuraGen to provide a clinical update conference call today at 5:00 p.m. ... Eastern Time -, BRANFORD, ...
Cached Medicine Technology:Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2 2CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference 2CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference 3CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference 4CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference 5CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference 6CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference 7CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference 8CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference 9
(Date:5/30/2015)... On Thursday, May 14, the ... and Dr. Evan Alley both of the University ... Experts’ series. The interview was part of the ... excellence. Drs. Simone and Alley were interviewed by ... whom they discussed the mesothelioma program at the ...
(Date:5/30/2015)... 2015 Responding to surging demand from ... experienced OGAWA products while abroad, OGAWA-engineered massage products have ... A leader in the Asian health and wellness industry ... developer and manufacturer of health and wellness equipment. ... their products, health enthusiasts in Asia and Australia, as ...
(Date:5/30/2015)... Cyclist Barry Haarde will commence his ... 2015: Piles of Miles” near San Francisco, California ... and encourage individuals to support needy hemophilic children ... Life supports nearly 1,200 impoverished children and adults ... sponsorships, scholarships and micro-enterprise grants. Hemophilia is a ...
(Date:5/30/2015)... iconic American actor, and host of “In America” James ... Medical Malpractice. This segment of “In America” will cover ... field. , According to the Bureau of Justice Statistics, ... roughly only 20% of them made it to court, ... remaining 30% were tossed out. (Source: http://www.bjs.gov/index.cfm?ty=tp&tid=4511 ) ...
(Date:5/30/2015)... (PRWEB) May 30, 2015 Venus Viva ... acne scars, large pores, deep wrinkles, stretch marks, pigmentation ... medical professional, such as Dr. F. Victor Rueckl of ... the clinical trials in Las Vegas. This body image ... into a system that delivers proven results through a ...
Breaking Medicine News(10 mins):Health News:Interview with Mesothelioma Experts, Drs. Simone and Alley Now Available on Demand 2Health News:Award-winning OGAWA Massage Chairs Finally Available for purchase in North America. 2Health News:Award-winning OGAWA Massage Chairs Finally Available for purchase in North America. 3Health News:Barry Haarde Cycles 4,000 Miles Across the USA for Hemophilia 2Health News:Announcing Ground-Breaking Technology for Anti-Aging, FDA Approved, Venus Viva. 2Health News:Announcing Ground-Breaking Technology for Anti-Aging, FDA Approved, Venus Viva. 3
... up to 24 patients ... ... Luke,s Medical Center,s,new hyperbaric chamber will triple the hospital,s capacity to ... (Photo: http://www.newscom.com/cgi-bin/prnh/20080417/AQTH107 ), The 52-foot-long, 66-ton chamber, the ...
... The American,Chemistry Council (ACC) today sent a letter ... update its review of the safety of bisphenol ... of scientific study regarding bisphenol A is well,documented ... concerns about the safety and use of polycarbonate ...
... The U.S. Agency for,International Development and Iraq,s Ministry ... (MOU) outlining a shared vision and,collaborative effort to ... health services to Iraqi citizens, and contribute to ... strengthens the strategic cooperation between the MoH and,USAID,s ...
... N.J., April 17 TeamStaff, Inc.,(Nasdaq: TSTF ), ... announced the results from the Company,s Annual,Meeting of Shareholders ... located,in Somerset, New Jersey., At the annual meeting, ... J. Delaney to serve as Class III Directors. In,addition, ...
... HVAC company provides tips for improving indoor air quality, ... National,Indoor Comfort Week, Atlas Butler Heating and Cooling is ... in their homes and offices,is free of harmful pollutants., ... indoor,environmental systems on which everyone relies, and honors the ...
... improved in patients , , THURSDAY, April 17 (HealthDay News) ... experimental Alzheimer,s drug reinforces the notion that the compound ... mild to moderate Alzheimer,s patients. , A second analysis ... also reveals that by improving the Alzheimer,s patients, ability ...
Cached Medicine News:Health News:Aurora St. Luke's Medical Center Installs the Country's Second-Largest Hyperbaric Chamber 2Health News:Aurora St. Luke's Medical Center Installs the Country's Second-Largest Hyperbaric Chamber 3Health News:Aurora St. Luke's Medical Center Installs the Country's Second-Largest Hyperbaric Chamber 4Health News:Aurora St. Luke's Medical Center Installs the Country's Second-Largest Hyperbaric Chamber 5Health News:Aurora St. Luke's Medical Center Installs the Country's Second-Largest Hyperbaric Chamber 6Health News:ACC Calls on FDA to Update Review of Bisphenol A 2Health News:ACC Calls on FDA to Update Review of Bisphenol A 3Health News:Iraq's Ministry of Health and USAID Sign Memorandum of Understanding to Increase Cooperation in Public Management 2Health News:TeamStaff, Inc. Announces Results From Annual Meeting of Shareholders 2Health News:TeamStaff, Inc. Announces Results From Annual Meeting of Shareholders 3Health News:National Indoor Comfort Week - A Breath of Fresh Air for Allergy Sufferers 2Health News:Experimental Alzheimer's Drug Shows Promise 2Health News:Experimental Alzheimer's Drug Shows Promise 3
Gills Colibri forceps, very fine pointed tips....
Fine tying forceps, curved tips, wide handle....
Castroviejo tying forceps, tying platforms, straight, 0.3 mm teeth....
Microsurgical curved forceps made of titanium has curved shafts with smooth working surface. TCI working parts 6 mm from tips with round handle, diam. 6 mm, overall length 116 mm....
Medicine Products: